A few years back, Nancy Klimas's lab invited PwME to send in their 23&me data for comparison with non-PwME. I think they determined that PwME were more likely to have an MTHFR gene mutation that might stuff up the conversion of folate to its active form, with important consequences. They were offering patients with that mutation a chance to take part in a 3-month trial of the active form of folate. That was the summer of 2018, I think. Any news?